Neil Woodford spent last week framing the controversy around Northwest Biotherapeutics as one of the "bumps in the road" that are inevitable when investing in biotechs. But with concerns about Northwest Bio being in the public domain prior to Woodford making his investment, the case has prompted the fund's backers to question what other "bumps" he may have failed to foresee.
Northwest Biotherapeutics is defying its big investor Neil Woodford, bypassing his candidate to run an independent investigation into allegations of financial misdeeds at the biotech and instead opting to engage a pair of attorneys to run the probe.
Neil Woodford has invested $95 million in Northwest Biotherapeutics and its controversial therapeutic cancer vaccine over the past year. And now that he has bought up 28% of the company's stock, he's pushing hard for an independent investigation into allegations of financial impropriety that have been in circulation since before he took his first big stake in the biotech.
Back in November, U.K. heavyweight investor Neil Woodford invested $25 million in Northwest Biotherapeutics in the hope that its brain cancer candidate would turn up good Phase III results. Now, Woodford has thrown another $40 million behind the Bethesda, MD-based biotech as it continues to work through Phase III.
High-profile U.K. investor Neil Woodford is putting more chips on the controversial Northwest Biotherapeutics, betting another $40 million on the company as it works through Phase III with a cancer vaccine.
U.K. biotech investment heavyweight Neil Woodford has invested $25 million in the U.S. biotech Northwest Biotherapeutics, gambling that its controversial Phase III study on a new therapeutic vaccine for brain cancer comes up a winner.
Anxious to prove that U.K. drug regulators aren't as slow and stodgy as they're often accused of being, British officials today announced the first in a new category of experimental drugs to earn the title of "Promising Innovative Medicine."
In recent years it's been the big biotechs in the U.S. which have registered approvals for the drugs most likely to succeed on the market. But in reviewing EvaluatePharma's recent picks for top Phase III drugs, it's interesting to see some prominent positions among the Big Pharma crowd. Read the full report >>
With the expected launch of Northwest Biotherapeutics' dendritic cell-based therapeutic vaccine DCVax-L, the glioblastoma multiforme drug market is expected to grow rapidly, from $305 million in 2012 to $583 million in 2019, according to market research.
The cancer vaccine field has seen its share of late-stage disappointments and outright flops, but a number of hopefuls are lining up to present new research backing their experimental shots at this year's upcoming American Society of Clinical Oncology Annual Meeting in Chicago.